GSK vs WRB · P/E 13, $103.31B cap vs P/E 17, rev $3.72B
GlaxoSmithKline PLC ADR (GSK) versus W. R. Berkley Corp (WRB) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
W. R. Berkley Corp (WRB) is a insurance - property & casualty company listed on US.
GSK does not have a complete income-statement cache yet.
Latest reported WRB revenue for 2026-06-30 was $3.72B. Net income was $452.3M. Revenue was up 0.7% from 2026-03-31 to 2026-06-30. WRB currently screens at market cap $27.12B and trailing P/E 16.6.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. WRB currently screens at market cap $27.12B and trailing P/E 16.6.
Not investment advice. Open the GSK and WRB stock pages for the full models.
Not investment advice.